Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Hilary Duff's husband responds to Ashley Tisdale's 'toxic' mom group claims: The drama, explained - 2NASA just launched Artemis 2. What happens today could make or break the moon mission
- 3Enormous Credit And All that You Really want To Be aware
- 4U.S. to drop childhood vaccine recommendations as it looks to Denmark, Washington Post reports
- 5Influencers are selling a delusional fantasy of being postpartum. Why is it so easy to believe?
- Peruvian ex-President Martin Vizcarra sentenced to 14 years in prison
- Fisherman Attacked by Great White Shark Says ‘My Left Foot Was in His Mouth’
- Evidence of lost baptismal rite stage uncovered in Byzantine era cathedral near Sea of Galilee
- Fact Check: Israeli Channel 13, Al Jazeera Did NOT Confirm Hezbollah Captured All Or Part Of Kiryat Shmona
- EU calls on Western Balkans to step up reforms for membership
- Public Parks in the USA
- Research highlights potential dangers of ultra-processed foods for women under 50 regarding precancerous polyps
- Figure out How to Analyze Medical attendant Compensation Patterns Across Different Specializations
- Satellite data reveals a huge solar storm in 2024 shrank Earth's protective plasma shield
